Clinical Trial: Post-Transplant Cyclophosphamide in Patients Aged >/= 70 Years Undergoing Haploidentical Transplant
Study Status: Completed
Recruit Status: RECRUITING
Condition: Hematologic Malignancies
Study Type: INTERVENTIONAL
Official Title: IIT2022-03-Paquette-GeriBMT: A Phase I Study of De-Escalation of Post-Transplant Cyclophosphamide Dosing in Patients Aged >/= 70 Years Undergoing Conditioning With Fludarabine and Total Body I
Brief Summary:
The purpose of this phase 1 study is to determine the optimal dose of the immune suppressive drug, cyclophosphamide, following standard allogeneic stem cell transplant in patients aged >/= 70 years with hematologic malignancies.
Read more